Xinlitai announced that the company successfully renewed their contracts with Foritan® and Xinlitine, and successfully negotiated new indications for Enalol®. They all remained in the 2026 edition of the national health insurance catalogue, and the medical insurance categories were all Class B. The Forlitan® and Cinritine agreement is valid from January 1, 2027 to December 31, 2028, and the Enalol® agreement is valid from January 1, 2027 to December 31, 2027. The new medical insurance catalogue will be officially implemented on January 1, 2027. This matter will not have a significant impact on the company's performance during the reporting period.

Zhitongcaijing · 2d ago
Xinlitai announced that the company successfully renewed their contracts with Foritan® and Xinlitine, and successfully negotiated new indications for Enalol®. They all remained in the 2026 edition of the national health insurance catalogue, and the medical insurance categories were all Class B. The Forlitan® and Cinritine agreement is valid from January 1, 2027 to December 31, 2028, and the Enalol® agreement is valid from January 1, 2027 to December 31, 2027. The new medical insurance catalogue will be officially implemented on January 1, 2027. This matter will not have a significant impact on the company's performance during the reporting period.